PT-141

Also known as: Bremelanotide, Vyleesi

Brand names: Vyleesi

Overview

Hypoactive sexual desire disorder (HSDD) in women

PT-141 (Bremelanotide) is an FDA-approved peptide medication marketed as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors like Viagra, PT-141 works through the central nervous system by activating melanocortin receptors involved in sexual arousal. Clinical trials demonstrated significant improvements in sexual desire and satisfaction.

Mechanism of Action

Melanocortin receptor agonist that activates central nervous system pathways involved in sexual arousal

Dosage Information

Parameter	Detail
Administration	Subcutaneous injection
Typical Dose	1.75mg as needed, at least 45 min before activity
Frequency	As needed

Side Effects

Reported adverse effects from clinical data and post-market surveillance

Common Side Effects

Nausea

Flushing

Injection site reactions

Headache

Vomiting

Serious Side Effects

Increases in blood pressure

Darkening of skin

Severe nausea

!Contraindications

Do not use this peptide if any of the following apply

Uncontrolled hypertension
Cardiovascular disease
Pregnancy
Breastfeeding

Clinical Evidence

Evidence Quality

High Quality

Clinical Trial Phase

Approved (post-market)

View Key Study

Cost Comparison

Estimated monthly costs compared to similar peptides

Peptide	Monthly Cost	FDA Status
PT-141	$800 - $1200/mo	FDA Approved
Melanotan II	$30 - $60/mo	Not submitted

Medical Disclaimer

The information provided on this page is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy or medication. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary.